Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Revenue projections:

Revenue projections for RMD
Revenue projections for RMD

RMD is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 3.060000
forwardPE 20.962992
debtToEquity 13.411000
earningsGrowth 0.145000
revenueGrowth 0.110000
grossMargins 0.614740
operatingMargins 0.351630
trailingEps 10.110000
forwardEps 12.179560

A current ratio of 3.06 for RMD implies that the company has ample liquidity to meet its short-term debts. RMD's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
RMD's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
ResMed Inc.'s low Debt-to-Equity ratio indicates that the company isn't over-leveraged, suggesting it maintains a healthy balance between debt and equity. This lowers financial risk and points to a stable financial foundation, reassuring investors of the company's financial health.
RMD's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
RMD's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
RMD's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for RMD's financial performance.

Price projections:

Price projections for RMD
Price projections for RMD

ResMed Inc.'s price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in ResMed Inc.'s ability to achieve future growth.

Insider Transactions:

Insider Transactions for RMD
Insider Transactions for RMD


44 sales of RMD stock were made, with market price at 249.30795565518466 per share.There were no sell transactions during the given period.The recent trend of increased buying at RMD's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for RMD
Recommendations trend for RMD


The recent buy bias from analysts suggests RMD is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, RMD appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.